Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New Scheduling Schedule: DEA Meets 90-Day Deadline For UCB’s Briviact

This article was originally published in RPM Report

Executive Summary

UCB’s Briviact (brivaracetam) is the first product cleared under a new accelerated process for new molecular entities subject to the Controlled Substances Act scheduling process. Will the focus shift to FDA’s timelines next?



Related Companies